Javascript must be enabled to continue!
A104 PATIENT AND PUBLIC INVOLVEMENT (PPIN) IN IBD RESEARCH - A SCOPING REVIEW
View through CrossRef
Abstract
Background
Over the past 10 years, interest in patient and public involvement (PPIn) in research has grown. Several arguments support the engagement of patients as partners in the research process. Patients with lived experience of a condition can offer their knowledge to study design as experience-based experts, helping researchers incorporate patient-pertinent outcomes. PPIn has also been shown to boost patient enrolment and retention in clinical trials. Benefits, challenges, and best practices of PPIn have been examined in other fields. However, to date, no study has examined PPIn in inflammatory bowel disease (IBD) research. Many factors amenable to research involvement may impact IBD patients’ quality of life, including disease morbidity, complications, and efficacy/side effects of therapy.
Aims
This review aims to characterize methods of PPIn in IBD research and highlight themes relating to best practices, benefits, and challenges.
Methods
We ran a systematic search on MEDLINE, EMBASE, and Cochrane for all IBD research studies in which IBD patients were involved in the research process. PPIn included but was not limited to patient input in one of the following 3 stages: Study Design (prioritization of research topics, outcome selection, study tool development), Study Execution (recruitment, data collection & analysis), and Dissemination of Research. After abstract and full-text screening, 14 studies were selected.
Results
Patients were recruited for PPIn through IBD and patient organizations (7/14), outpatient clinics (4/14), tertiary care sites (2/14), and pre-existing patient advisory groups (1/14). The majority of studies (11/14) engaged patients in the development of study materials, which included a physical activity intervention for stoma patients, an IBD pregnancy decision aid, and a quality of life questionnaire. Two studies interviewed patients to determine comprehensibility of survey items and guide revisions. One study involved patients in data analysis and manuscript development. Most consultations were open-ended, including focus groups (8/14) and semi-structured interviews (3/14). According to study authors, PPIn helps guide IBD research priorities by focusing on patient-relevant issues. Authors also cited the role of PPIn in designing patient-friendly study tools. One challenge reported by 2 studies was that PPIn requires patients to have access to high-quality information and requires a significant time commitment, which may contribute to demographic biases.
Conclusions
The majority of IBD studies engaged patients in an open-ended format and were engaged in study design, particularly in developing study materials. Authors recommend continuous involvement of patients throughout the research process to address their research priorities.
Funding Agencies
None
Oxford University Press (OUP)
Title: A104 PATIENT AND PUBLIC INVOLVEMENT (PPIN) IN IBD RESEARCH - A SCOPING REVIEW
Description:
Abstract
Background
Over the past 10 years, interest in patient and public involvement (PPIn) in research has grown.
Several arguments support the engagement of patients as partners in the research process.
Patients with lived experience of a condition can offer their knowledge to study design as experience-based experts, helping researchers incorporate patient-pertinent outcomes.
PPIn has also been shown to boost patient enrolment and retention in clinical trials.
Benefits, challenges, and best practices of PPIn have been examined in other fields.
However, to date, no study has examined PPIn in inflammatory bowel disease (IBD) research.
Many factors amenable to research involvement may impact IBD patients’ quality of life, including disease morbidity, complications, and efficacy/side effects of therapy.
Aims
This review aims to characterize methods of PPIn in IBD research and highlight themes relating to best practices, benefits, and challenges.
Methods
We ran a systematic search on MEDLINE, EMBASE, and Cochrane for all IBD research studies in which IBD patients were involved in the research process.
PPIn included but was not limited to patient input in one of the following 3 stages: Study Design (prioritization of research topics, outcome selection, study tool development), Study Execution (recruitment, data collection & analysis), and Dissemination of Research.
After abstract and full-text screening, 14 studies were selected.
Results
Patients were recruited for PPIn through IBD and patient organizations (7/14), outpatient clinics (4/14), tertiary care sites (2/14), and pre-existing patient advisory groups (1/14).
The majority of studies (11/14) engaged patients in the development of study materials, which included a physical activity intervention for stoma patients, an IBD pregnancy decision aid, and a quality of life questionnaire.
Two studies interviewed patients to determine comprehensibility of survey items and guide revisions.
One study involved patients in data analysis and manuscript development.
Most consultations were open-ended, including focus groups (8/14) and semi-structured interviews (3/14).
According to study authors, PPIn helps guide IBD research priorities by focusing on patient-relevant issues.
Authors also cited the role of PPIn in designing patient-friendly study tools.
One challenge reported by 2 studies was that PPIn requires patients to have access to high-quality information and requires a significant time commitment, which may contribute to demographic biases.
Conclusions
The majority of IBD studies engaged patients in an open-ended format and were engaged in study design, particularly in developing study materials.
Authors recommend continuous involvement of patients throughout the research process to address their research priorities.
Funding Agencies
None.
Related Results
Autonomy on Trial
Autonomy on Trial
Photo by CHUTTERSNAP on Unsplash
Abstract
This paper critically examines how US bioethics and health law conceptualize patient autonomy, contrasting the rights-based, individualist...
An Inflammatory Bowel Diseases Integrated Resources Portal (IBDIRP)
An Inflammatory Bowel Diseases Integrated Resources Portal (IBDIRP)
Abstract
IBD, including ulcerative colitis and Crohn’s disease, is a chronic and debilitating gastrointestinal disorder that affects millions of people worldwide. Re...
P033 Cytomegalovirus colitis: Does concomitant inflammatory bowel disease lead to worse clinical outcomes? Descriptive study from a single-centre experience
P033 Cytomegalovirus colitis: Does concomitant inflammatory bowel disease lead to worse clinical outcomes? Descriptive study from a single-centre experience
BACKGROUND:
The association between cytomegalovirus (CMV) colitis and inflammatory bowel diseases (IBD) is well documented. Current studies estimate a 2% risk of CMV re...
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
P0107 Bronchiectasis as an underrecognized extra-intestinal manifestation of Inflammatory Bowel Disease
P0107 Bronchiectasis as an underrecognized extra-intestinal manifestation of Inflammatory Bowel Disease
Abstract
Background
Inflammatory bowel disease (IBD) often presents with extra-intestinal manifestations (EIMs). Pulmonar...
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
P125 Ankylosing spondylitis can influence the outcome of inflammatory bowel disease
P125 Ankylosing spondylitis can influence the outcome of inflammatory bowel disease
Abstract
Background
Both inflammatory bowel disease (IBD) and ankylosing spondylitis (AS) are inflammatory diseases but there wa...
N32 Outcome of joint IBD Obstetrics clinic in East Kent Hospital NHS Trust
N32 Outcome of joint IBD Obstetrics clinic in East Kent Hospital NHS Trust
Abstract
Background
IBD affects 2-3% of women in reproductive age group. Pregnant women often have concerns over IBD medi...

